Journal
BIOLOGICAL PSYCHIATRY
Volume 81, Issue 1, Pages 78-85Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2016.10.011
Keywords
Antipsychotics; Arrestin; Dopamine; Functional selectivity; Schizophrenia; System bias
Categories
Funding
- National Institutes of Health Grant [5R37-MH-073853, 5U-19-MH-082441]
- Pall Family Foundation
- Sidney R. Baer Jr. Foundation
- NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH073853, U19MH082441] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The dopamine D-2 receptor (D2R) is a G protein-coupled receptor that is a common target for antipsychotic drugs. Antagonism of D2R signaling in the striatum is thought to be the primary mode of action of antipsychotic drugs in alleviating psychotic symptoms. However, antipsychotic drugs are not clinically effective at reversing cortical-related symptoms, such as cognitive deficits in schizophrenia. While the exact mechanistic underpinnings of these cognitive deficits are largely unknown, deficits in cortical dopamine function likely play a contributing role. It is now recognized that similar to most G protein-coupled receptors, D(2)Rs signal not only through canonical G protein pathways but also through noncanonical beta-arrestin2-dependent pathways. We review the current mechanistic bases for this dual signaling mode of D(2)Rs and how these new concepts might be leveraged for therapeutic gain to target both cortical and striatal dysfunction in dopamine neurotransmission and hence have the potential to correct both positive and cognitive symptoms of schizophrenia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available